<DOC>
	<DOCNO>NCT02568839</DOCNO>
	<brief_summary>The purpose trial evaluate efficacy toxicity either combination docetaxel , trastuzumab sc pertuzumab ( arm A ) trastuzumab emtansin ( arm B ) . Switch therapy opposite treatment alternative applicable case lack response two course treatment , medical reason exceptional circumstance ( drug reaction , medical condition ) point . After termination primary treatment follow-up five year . A translational subprotocol mandatory part study protocol , exception use PET-CT evaluation .</brief_summary>
	<brief_title>Neoadjuvant Response-guided Treatment HER2 Positive Breast Cancer</brief_title>
	<detailed_description>Patients HER2-positive tumor &gt; 20 mm verfied regional lymph node metastases randomize either arm A , combination docetaxel , trastuzumab sc ( Herceptin SC® ) pertuzumab ( Perjeta® ) arm B , trastuzumab emtansin ( Kadcyla® ) . Switch opposite treatment perform case lack response evaluation mammography ultrasound , alternatively MRI breast 2nd , 4th 6th course treatment . Postoperative treatment , trastuzumab , radiotherapy , eventual endocrine treatment ) accord standard guideline . Structured follow-up visit yearly five year , include report persistent treatment-related toxicity , HRQoL , recurrence death . The trial contains also translational subprotocol : 1 . PET-CT use FDG , confine chest , perform start , 2nd 6th course ( functional imaging , optional ) . 2 . Core biopsy tumor collected start 2nd course treatment . If residual tissue available , sample collect surgical sample 3 . Blood sample collect repeatedly ongoing treatment yearly follow-up 4 . FNAs metastases case recurrence follow-up</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Written inform consent 2 . Patients breast cancer confirm histology , characterize immunohistochemistry ER , PR , HER2 proliferation marker 3 . Tumor blood sample available . HER2 type confirm ISH 4 . Age 18 year old . Elderly patient condition adequate plan therapy 5 . Primary breast cancer &gt; 20mm diameter and/or verify lymph node metastases 6 . Adequate bone marrow , renal , hepatic cardiac function uncontrolled medical psychiatric disorder 7 . LVEF ≥55 % 8 . ECOG performance status 01 9 . Primary breast cancer define p. 5 plus 2 morphologically characterize welldefined distant metastasis accessible stereotactic radiotherapy , provide treatment available 1 . Distant metastasis , include node metastasis contralateral thoracic region mediastinum 2 . Other malignancy diagnose within last five year , except radically treat basal squamous cell carcinoma skin CIS cervix 3 . Patients childbearing age without adequate contraception 4 . Pregnancy lactation 5 . Uncontrolled hypertension , heart , liver , kidney relate medical psychiatric disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Neoadjuvant therapy</keyword>
</DOC>